Want create site? Find Free WordPress Themes and plugins.

TGV-Therapeutics is a biopharmaceutical company focused on the development of novel drugs that can address unmet clinical needs in the treatment of life-threatening systemic fungal infections.

Our lead product candidate, MYC-053, is a novel, antifungal agent that is structurally distinct from the three main classes of antifungal antibiotics. The effectiveness of MYC-053 against the currently incurable multidrug-resistant fungal infections is attributed to its distinct chemical structure. We developed MYC-053 as an oral drug primarily for the treatment of harmful fungal diseases in humans.

Did you find apk for android? You can find new Free Android Games and apps.